Cardiac Structural Remodeling and Hemodynamic Patterns Following Transcatheter Aortic Valve Replacement

Julien Feghaly 1, Debapria Das 2, Zachary Oman 2, Steven Smart 2

1. Cardiology, University of Florida College of Medicine, Jacksonville, USA 2. Cardiology, Saint Louis University School of Medicine, Saint Louis, USA

Corresponding author: Julien Feghaly, julien.feghaly@jax.ufl.edu

Abstract

Background
Transcatheter aortic valve replacement (TAVR) is increasingly utilized for most patients with symptomatic severe aortic stenosis. TAVR is linked to enhanced long-term cardiac hemodynamics, reversal of left ventricle (LV) hypertrophy, and improved aortic valve gradients. We present a retrospective observational study assessing cardiac remodeling and valvular flow patterns post-TAVR.

Methods
Retrospective echocardiographic data were collected, evaluating cardiac function and valvular flow patterns before and after TAVR at a single institution. Data was compiled and statistically analyzed using a paired t-test evaluating variations at approximately 30 days and one-year post-TAVR.

Results
On echocardiogram 30 days and one-year post-TAVR, there was a reduction in LV mass index from 132 g/m² to 110 g/m² (95%CI: 98-122; p=0.01) and 118 g/m² (95%CI: 102-133; p=0.03), and a reduction in relative wall thickness from 0.54 to 0.49 (95%CI: 0.46-0.52; p=0.05) and 0.44 (95%CI: 0.38-0.49; p=0.03), respectively. Doppler velocity indices (DVI) increased from 0.24 to 0.61 (95%CI: 0.49-0.73; p<0.001) and 0.57 (95%CI: 0.48-0.65; p<0.001). Expected improvement in aortic valve velocities and gradients were observed post-TAVR.

Conclusions
Following TAVR, LV remodeling can be observed as early as 30 days. This is demonstrated by a reduction in LV mass index and relative wall thickness in conjugation with an anticipated improvement in valvular flow patterns and flow across the aortic valve.

Introduction
Since 2011, the PARTNER (Placement of AoRTic TranScatheter Valve Trial) has paved the way demonstrating that transcatheter aortic valve replacement (TAVR) was equal in outcomes to surgical aortic valve replacement (SAVR) in severe aortic stenosis (AS) patients of high surgical risk [1]. In 2019, the benefits of TAVR have expanded to include patients of low surgical risk, demonstrating lower rates of death, stroke, or rehospitalization at one year compared to SAVR [2]. The 2020 AHA/ACC Valve guidelines went on to specifically recommend transfemoral TAVR in preference to SAVR in severe AS patients who are >80 years old in the presence of suitable vascular anatomy [3]. Over the next decade, it can be expected that TAVR frequency increase as treatment of choice for many severe AS patients, excluding patients with severe AS who are <65 years of age or have a life expectancy >20 years [3].

Various studies have gone on to examine long-term clinical outcomes [4,5] and valve durability and structural integrity [6] post-TAVR. Echocardiography has demonstrated that TAVR is associated with a reduction of the aortic valve gradients, improved hemodynamics, and regression of left ventricle (LV) hypertrophy [7,8]. Yet, data describing the prosthetics aortic valve’s hemodynamics and cardiac remodeling patterns over time is limited within the published literature. Echocardiography is the recommended imaging modality of choice in assessing valvular performance, cardiac function, and long-term follow-up [9].

Therefore, we aimed to perform a retrospective observational study examining cardiac remodeling and valvular flow patterns 30 days up to one year following TAVR at a single institution.
Materials And Methods

Study design
A retrospective observational study was performed evaluating electronic medical records and echocardiographic data of patients that had undergone TAVR at a single institution (Saint Louis University, Missouri, USA), a tertiary-care hospital and referral center serving urban, suburban, and rural communities. The Saint Louis University Institutional Review Board approved the protocol (protocol number: 30365). No patient consent was obtained as the study design qualified as secondary research involving only medical records review. All collected patient and echocardiographic data were de-identified.

Study outcome
The primary outcome of the study was to observe the reduction in LV mass index, in addition to the expected increase in the aortic valve area and decrease in aortic velocities and gradients post-TAVR. Secondary outcomes included the evaluation of all other cardiac remodeling and valvular flow patterns over time.

Patient selection
Between August 2015 and September 2019, 129 adult patients underwent TAVR at our institution. All patients’ electronic medical records and echocardiographic data were evaluated for inclusion in the study. Echocardiographic data needed to be available both before and after TAVR; data post-TAVR would need to be available at approximately 30 days, one-year, or at both time points. Patients with missing echocardiographic data were excluded. These included patients who were deceased post-TAVR or patients referred for TAVR that were being followed by physicians at outside institutions. Patients that had undergone any type of aortic valve implantation/replacement procedure (TAVR or SAVR) prior to the documented TAVR were excluded (11 patients). Following records evaluation, 66 patient records met the inclusion criteria for the study.

Data collection
At the institution, prior to undergoing TAVR, patients would require an echocardiogram for the evaluation of aortic stenosis. Once the TAVR was completed a post-TAVR echocardiogram was scheduled at approximately 30 days to re-evaluate the aortic valve’s hemodynamics and cardiac function. This would then be followed by long-term follow-up with the primary physician or Cardiologist, who may or may not re-order an echocardiogram at approximately one-year, based on clinical indication.

Data on patient characteristics at the time of TAVR were collected from the electronic medical records. This data included age, sex, social history, medical comorbidities, functional status, and the type of implanted aortic valve. Echocardiography data were extracted from the electronically available imaging and numeric data. Echocardiograms were performed by in-patient or out-patient echocardiogram laboratories. As the data were collected retrospectively, there was no standardization for sonographic acquisition or interpretation of echocardiograms.

Data were collected on Society of Thoracic Surgeons (STS) and Kansas City Cardiomyopathy Questionnaire (KCCQ) scores before TAVR. The STS score is used to calculate a patient’s risk of mortality and morbidity from cardiac surgery [10]. The KCCQ score is a tool used to provide an understanding of a heart failure patient’s quality of life and predict clinical outcomes over time. Its domains include the patient’s physical limitations, symptoms description, self-efficacy, knowledge, social interference, and health-related quality of life. It is based on a 0 to 100 point scale: 0 to 24: very poor to poor; 25 to 49: poor to fair; 50 to 74: fair to good; and 75 to 100: good to excellent [11].

Statistical analysis
Data were evaluated for normal distribution using box and Q-Q plot analysis, and extreme outliers were rejected using the Inter Quartile Range method. Continuous echocardiographic numerical variables were statistically analyzed using a paired t-test evaluating variations at approximately 30 days and one-year post-TAVR. All testing used a two-sided alpha level of 0.05. Continuous variables are presented as mean ± standard deviation or along with 95% confidence intervals where applicable. All statistical analyses were performed with the use of R Studio version 1.2.1335, part of the R statistical software [12].

Results
The majority of patients included in the study were older (mean 76 years old) and had hypertension (94%). The distribution of females to males was approximately equal (53% female, 47% male). Patients pre-TAVR had intermediate STS scores (between 4% and 8%) and poor to fair mean KCCQ scores (45, 95% confidence interval [CI]: 39-52) [Table 1].
| Mean ± SD | n (%) |
|-----------|-------|
| Age, years | 76 ± 10 | 8 (12) |
| STS score | 5.8 ± 5.3 | 43 (65) |
| KCCQ: pre-TAVR | 45 ± 27 | 18 (27) |
| KCCQ: 30-day post-TAVR | 76 ± 24 | 17 (26) |
| KCCQ: 1-year post-TAVR | 73 ± 26 | 12 (18) |
| Sex: | | |
| Male | 31 (47) | 5 (8) |
| Female | 35 (53) | 20 (30) |
| Smoking status: | | |
| Current | 4 (6) | NYHA class: |
| Former | 37 (56) | I | 1 (2) |
| Never | 25 (38) | II | 26 (39) |
| Alcohol use | 21 (32) | III | 34 (52) |
| HTN | 62 (94) | IV | 5 (8) |
| HLD | 35 (53) | Valve used: |
| DM | 34 (52) | CoreValve | 57 (86) |
| Afib or Aflut | 18 (27) | Edwards-S3 | 9 (14) |

**TABLE 1: Patient Characteristics**

ACS: acute coronary syndrome, Afib or Aflut: atrial fibrillation or atrial flutter, CABG: coronary artery bypass grafting, CAD: coronary artery disease, CKD: chronic kidney disease, COPD: chronic obstructive pulmonary disease, CVA/TIA: cerebrovascular accident/transient ischemic attack, DM: diabetes mellitus, HLD: hyperlipidemia, HTN: hypertension, KCCQ: Kansas City Cardiomyopathy Questionnaire score, NYHA: New York Heart Association, OSA: obstructive sleep apnea, PM or ICD: pacemaker or implantable cardioverter-defibrillator, Pulm HTN: pulmonary hypertension, PVD: peripheral vascular disease, SD: standard deviation, STS: Society of Thoracic Surgeons score

Echocardiographic data were organized into timepoint following TAVR: first echocardiogram (mean: 33 days) and post-TAVR follow-up echocardiogram (mean: 327 days). On 30-day and one-year follow-up echocardiograms post-TAVR, there was a reduction in LV mass index from 132 g/m² to 110 g/m² (95%CI: 98-122; p<0.01) and 118 g/m² (95%CI: 102-133; p<0.05) and a reduction in relative wall thickness from 0.54 to 0.49 (95%CI: 0.46-0.52; p=0.05) and 0.44 (95%CI: 0.38-0.49; p=0.03), respectively, KCCQ scores improved from 45 to 76 on 30-day (95%CI: 69-83; p<0.001) and 73 on one-year (95%CI: 64-82; p<0.001) follow-up post-TAVR.

A predictable reduction in aortic valve velocities and gradients was observed. In addition, to an expected post-prothesis implantation increase in doppler velocity indices (DVI) from 0.24 to 0.61 (95%CI: 0.49-0.73; p<0.001) and 0.57 (95%CI: 0.48-0.65; p<0.001) and LVOT (left ventricular outflow tract) peak velocity and gradient at 30-day and one-year follow-up. No statistically significant changes nor trends for improvement or deterioration were noted for aortic insufficiency, other valvular flow patterns, right ventricular function, or ejection fraction on follow-up echocardiograms [Table 2].

| Pre-TAVR echocardiogram (n=66) | Post-TAVR first echocardiogram (mean: 33 days) (n=62) | Post-TAVR follow-up echocardiogram (mean: 327 days) (n=31) |
|-------------------------------|------------------------------------------------------|-------------------------------------------------------|
| Mean ± SD | 95% CI | Mean ± SD | 95% CI | p-value | Mean ± SD | 95% CI | p-value |
| Metric                                      | Value                          | Reference Value | p-value  |
|--------------------------------------------|--------------------------------|-----------------|----------|
| LV mass, g                                 | 248 ± 110 (221, 276)           | NA              | 0.06     |
| LV mass index, g/m²                        | 132 ± 56 (118, 146)           | 110 ± 39 (98, 122) | *0.01   |
| RWT                                        | 0.54 ± 0.14 (0.51, 0.58)      | 0.49 ± 0.10 (0.46, 0.52) | *0.05   |
| LV ejection fraction, %                    | 58 ± 14 (54, 61)              | 57 ± 14 (53, 60)   | 0.76     |
| AV mean gradient, mmHg                     | 35 ± 14 (32, 38)              | 8 ± 4 (7, 9)      | *<0.001 |
| AV mean velocity, cm/s                     | 276 ± 71 (259, 294)           | 127 ± 50 (95, 159) | *<0.001 |
| AV peak gradient, mmHg                     | 60 ± 24 (54, 65)              | 16 ± 8 (14, 18)   | *<0.001 |
| AV peak velocity, cm/s                     | 376 ± 77 (358, 395)           | 187 ± 62 (171, 203) | *<0.001 |
| AV VTI, cm                                 | 89 ± 26 (83, 96)              | 41 ± 11 (34, 47)  | *<0.001 |
| AV area, cm²                               | 0.77 ± 0.21 (0.71, 0.82)      | 1.79 ± 0.47 (1.63, 1.95) | *<0.001 |
| AV area index, cm²/m²                      | 0.40 ± 0.12 (0.37, 0.43)      | 0.88 ± 0.22 (0.80, 0.96) | *<0.001 |
| Aortic root diameter, cm                   | 3.1 ± 0.5 (3.0, 3.3)          | 3.2 ± 0.5 (3.0, 3.3) | 0.67    |
| LVOT diameter, cm                          | 2.1 ± 0.2 (2.0, 2.1)          | 2.1 ± 0.2 (2.0, 2.1) | 0.56    |
| LVOT peak velocity, cm/s                   | 92 ± 27 (85, 98)              | 96 ± 27 (89, 104)  | 0.19    |
| LVOT peak gradient, mmHg                   | 3.6 ± 2.2 (3.1, 4.2)          | 4.9 ± 2.4 (3.3, 6.5) | 0.088   |
| LVOT mean velocity, cm/s                   | 71 ± 43 (61, 82)              | 79 ± 15 (69, 89)   | 0.10    |
| LVOT mean gradient, mmHg                   | 1.9 ± 1.0 (1.7, 2.2)          | 3.0 ± 1.2 (2.3, 3.8) | 0.06    |
| LVOT VTI, cm                               | 20.7 ± 5.9 (19.2, 22.2)       | 22.3 ± 5.3 (19.2, 25.4) | 0.57    |
| LVOT stroke volume, ml                     | 68 ± 22 (62, 73)              | 69 ± 10 (60, 79)   | 0.55    |
| LVOT stroke volume index, ml/m²             | 35 ± 12 (32, 38)              | 35 ± 9 (30, 41)    | 0.61    |
| LVOT cardiac output, ml/min                | 5110 ± 1570 (4720, 5500)      | 5364 ± 1550 (3440, 7290) | 0.25    |
| LVOT cardiac index, ml/min/m²              | 2680 ± 770 (2490, 2870)       | 2660 ± 900 (1540, 3770) | 0.23    |
| DVI with LVOT VTI                          | 0.24 ± 0.08 (0.22, 0.26)      | 0.61 ± 0.19 (0.49, 0.73) | *<0.001 |
| AI peak velocity, cm/s                     | 377 ± 51 (364, 390)           | 357 ± 20 (306, 407) | NA      |
| AI peak gradient, mmHg                     | 60 ± 16 (56, 63)              | 51 ± 6 (41, 60)   | NA      |
| AI pressure halftime, ms                  | 344 ± 82 (325, 365)           | 448 ± 42 (344, 552) | NA      |
| MV peak velocity, cm/s                     | 208 ± 159 (169, 248)          | 178 ± 55 (138, 217) | 0.93    |
| MV peak gradient, mmHg                     | 9 ± 7 (8, 11)                 | 14 ± 7 (9, 19)    | 0.58    |
| Mitral E Point Velocity, cm/s              | 115 ± 42 (105, 126)           | 117 ± 45 (104, 129) | 0.67    |
| Mitral A Point Velocity, cm/s              | 101 ± 49 (89, 113)            | 116 ± 43 (103, 129) | 0.09    |
| Mitral E to A Ratio                        | 1.4 ± 0.9 (1.1, 1.6)         | 1.1 ± 0.6 (0.9, 1.2) | 0.07   |
TABLE 2: Study Echocardiographic Findings

|                          | MV area, cm | PASP, mmHg | LA diameter, cm | LA volume, cm³ | LA volume index, cm²/m² | PV Peak Velocity, cm/s | PV Peak Gradient, mmHg | TAPSE, mm | KCCQ |
|--------------------------|-------------|------------|----------------|----------------|-------------------------|------------------------|------------------------|---------|------|
|                          | 3.1 ± 1.1   | 51 ± 16    | 4.5 ± 0.8      | 85 ± 37        | 44 ± 19                  | 105 ± 27               | 4.7 ± 2.0              | 20 ± 4  | 45 ± 27 |
|                          | (2.9, 3.4)  | (47, 55)   | (4.3, 4.7)     | (75, 94)       | (40, 49)                 | (99, 112)              | (4.2, 5.2)             | (19, 21)| (39, 52)|
|                          | 2.3 ± 0.9   | 52 ± 14    | 4.3 ± 0.7      | 85 ± 38        | 41 ± 16                  | 106 ± 28               | 4.1 ± 1.4              | 23 ± 3  | 76 ± 24 |
|                          | (1.5, 3.0)  | (34, 69)   | (4.1, 4.5)     | (45, 125)      | (26, 56)                 | (98, 114)              | (3.3, 5.1)             | (15, 30)| (69, 83)|
|                          | 0.57        | 0.95       | 0.11           | 0.09           | 0.17                    | 0.62                   | 0.69                  | 0.80    | *<0.001|
|                          | 2.8 ± 1.3   | 43 ± 7     | 4.6 ± 0.6      | 105 ± 21       | 55 ± 17                  | 91 ± 24                | 3.4 ± 1.8              | 17 ± 4  | 73 ± 26 |
|                          | (1.9, 3.6)  | (36, 50)   | (4.4, 4.9)     | (92, 119)      | (46, 63)                 | (81, 101)              | (2.5, 4.2)             | (15, 20)| (64, 82)|
|                          | 0.07        | 0.13       | 0.31           | 0.11           | 0.08                    | 0.18                   | 0.18                  | 0.63    | *<0.001|

*p-statistically significant, p-value <0.05
AI: aortic insufficiency, AV: aortic valve, CI: confidence interval, DVI: doppler velocity index, KCCQ: Kansas City Cardiomyopathy Questionnaire score, LA: left atrium, LV: left ventricle, LVOT: left ventricular outflow tract, MV: mitral valve, NA: not available, PASP: pulmonary artery systolic pressure, PV: pulmonary valve, RWT: relative wall thickness, SD: standard deviation, TAPSE: tricuspid annular plane systolic excursion, TAVR: transcatheter aortic valve replacement, VTI: velocity time integral

Discussion

As anticipated, TAVR is associated with an immediate and sustained reduction in transaortic pressure gradients and an increase in the aortic valve area [13]. Flow-dependent parameters of AV peak velocity, peak gradient and mean gradient are expected to decrease over time, given changes in intravascular volume status, myocardial loading, and heart rate. While, flow-independent parameters aortic valve area (AVA), AVA index, and DVI are expected to not change on follow-up echocardiography compared to the first echocardiogram post-TAVR [7].

Aortic stenosis leads to LV pressure overload, LV hypertrophic remodeling, and an increase in relative wall thickness. Following TAVR, a hemodynamic improvement is expected following correction of stenosis and is complemented with immediate improvement in LV systolic function and gradual LV mass and relative wall thickness reduction [13]. In turn, this reveals LV plasticity and the ability for regression of LV hypertrophy over time. Prior studies have noted a regression in LV mass index after 30 days, one year [13], and five years [7]. Our data similarly demonstrated LV remodeling and regression in LV mass index on post-TAVR follow-up echocardiograms at 327 days. Early regression of LV mass index at 30 days post-TAVR has been associated with decreased hospitalization rates and improved morbidity at one year [14]. On 2-5 year follow-up, every 10% reduction in LV mass index is associated with a 5% reduction in all-cause mortality [15].

Despite a significant improvement in LV mass index, hemodynamic changes demonstrated a non-statistically significant trend towards improved LVOT stroke volume, stroke volume index, cardiac output, and cardiac index on follow-up echocardiograms, similar to prior studies [16]. Comparably, we did not observe an anticipated significant change in ejection fraction post-TAVR. Once deployed, it is expected for the TAVR to reduce myocardial contractility and impair diastolic function, followed by an improvement in ejection fraction after 30 days. This phenomenon is thought to be secondary to temporary myocardial stunning provoked by rapid ventricular pacing during TAVR [16].

Our finding of increased LVOT peak velocity and gradient on post-TAVR echocardiograms is likely secondary to the expected increase in peak velocity and gradient from the pre-stent LVOT location to the pre-leaflet in-stent location [7]. As evident by our results, ensuring accuracy is imperative in the measurements at pre-stent LVOT and pre-leaflet in-stent locations, as these measurements will determine the consistency of TAVR echocardiographic value performance evaluation. However, to better evaluate a TAVR prosthesis, the Doppler velocity index can be measured. DVI is a dimensionless ratio of the proximal LVOT velocity to the flow through the aortic valve prosthesis. It incorporates the effect of flow on velocity through the valve while being less dependent on valve size. It can be calculated as the ratio of the respective velocity-time integrals and approximated to the peak velocities. DVI is always less than one and a DVI of <0.25 is suggestive of significant prosthetists obstruction. Our patients had DVI 0.61 and 0.57 at 30-day and one-year echocardiograms, respectively. Thus, demonstrating lack of obstruction and possibly better outcomes as recent studies suggest that self-expanding valve DVI <0.50 following TAVR has higher three-year mortality (24.0% vs. 18.5%, p=0.025) [17].
Aortic insufficiency was not demonstrated on follow-up echocardiograms post-TAVR. Indeed, the absence of aortic insufficiency is supportive of good long-term valve durability, and its presence is associated with suboptimal late clinical outcomes and increased mortality [18]. In high and intermediate-risk patients, TAVR compared to surgical replacement has lower rates of 30-day mortality, stroke, and hospitalization, improved functional status, shorter duration of hospitalization, and lower rates of procedural complications [19]. Clinical outcomes on mortality and hospitalizations were not examined in our study; however, KCCQ scores on follow-up demonstrated significant improvement in heart failure patients’ quality of life, emphasizing TAVR’s meaningful impact on patient morbidity.

Study limitations
Our study was retrospective in design. Patients’ initial evaluation and echocardiograms pre- or post-TAVR were performed at our institution or other local institutions before referral to our institution. The available echocardiographic numerical and imaging data were limited. Echocardiograms were not performed in a single echocardiographic laboratory allowing for standardization, quality control of image analysis, and reproducibility, resulting in operator bias while performing and reading the echocardiograms. Moreover, transthoracic echocardiography may have prevented optimal evaluation of AV leaflet motion and possible subclinical valve thrombosis.

The sample size was notably decreased at one-year follow-up, possibly secondary to follow-up at other local institutions, loss to follow-up, or mortality. Data on mortality and hospitalizations was not available. The study was derived from data of a high-risk population with multiple comorbidities and a high mortality rate, which led to difficulty in long-term follow-up influenced by survival bias. Data was not available on hypertension management post-TAVR, as better blood pressure control may have played a role in LV remodeling over time. Future larger randomized prospective studies are needed to increase the quality of the echocardiographic and clinical data.

Conclusions
TAVR demonstrates regression in LV mass index, relative wall thickness, and improvement in aortic valve flow patterns and hemodynamics. This leads to LV remodeling and regression of LV hypertrophy, which has been associated with decreased hospitalization rates, improved morbidity, and a reduction in all-cause mortality. Additionally, post-TAVR KCCQ scores demonstrated a clinically significant improvement in heart failure patients’ quality of life and morbidity. As TAVR continues to be the treatment of choice for the majority of severe aortic stenosis patients in the coming years, we will continue to further understand its associated echocardiographic remodeling patterns and long-term outcomes.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Saint Louis University Institutional Review Board issued approval 30565. NOTICE OF INSTITUTIONAL REVIEW BOARD APPROVAL Date: August 09, 2019 To: Smart, Steven, Ctr Comprehensive Cardiovasc C From: Kisselev, Oleg, Chairperson, Professor, Minimal Risk #2 Protocol Number: 30565 The above-listed protocol was reviewed and approved by the Saint Louis University Institutional Review Board. Assurance No: FWA00005304 Below are specifics of approval: Form Type: NEW Level of Review: EXEMPT #4 Form Approval Date: August 07, 2019 HIPAA Compliance: Code Access Agreement The Saint Louis University Institutional Review Board complies with the regulations outlined in 45 CFR 46, 45 CFR 164, 21 CFR 50 and 21 CFR 56 and has determined the specific components above to be in compliance with these regulations, as applicable.

Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Smith CR, Leon MB, Mack MJ, et al.: Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011, 364:2187-98. 10.1056/NEJMoa1103510
2. Mack MJ, Leon MB, Thourani VH, et al.: Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019, 380:1695-705. 10.1056/NEJMoa1814052
3. Otto CM, Nishimura RA, Bonow RO, et al.: 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. Circul. 2021, 143:e72-e227. 10.1161/CIR.0000000000000925
4. Mack MJ, Leon MB, Smith CR, et al.: 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet. 2015, 385:2477-84. 10.1016/S0140-6736(15)60308-7
5. Gleason TG, Reardon MJ, Popma JJ, et al.: 5-year outcomes of self-expanding transcatheter versus surgical...
aortic valve replacement in high-risk patients. J Am Coll Cardiol. 2018, 72:2687-96. 10.1016/j.jacc.2018.08.2146
6. Barbanti M, Petronio AS, Ettori F, et al.: 5-year outcomes after transcatheter aortic valve implantation with CoreValve prosthesis. JACC Cardiovasc Implant Dev. 2015, 8:1084-91. 10.1016/j.jcin.2015.05.024
7. Daubert MA, Weisnman NJ, Hahn RT, et al.: Long-term valve performance of TAVR and SAVR: a report from the PARTNER I trial. JACC Cardiovasc Imaging. 2017, 10:15-25. 10.1016/j.jcmg.2016.11.004
8. Feghaly J, Oman Z, Das D, Smart S: Cardiac hemodynamic and remodeling patterns following transcatheter aortic valve replacement. J Investig Med. 2020, 68:1027-1028.
9. Zoghbi WA, Asch FM, Bruce C, et al.: Guidelines for the evaluation of valvular regurgitation after percutaneous valve repair or replacement. J Am Soc Echocardiogr. 2019, 32:431-75. 10.1016/j.echo.2019.01.003
10. Jin R, Furnary AP, Fine SC, Blackstone EH, Grunkemeier GL: Using society of thoracic surgeons risk models for risk-adjusting cardiac surgery results. Ann Thorac Surg. 2010, 89:677-82. 10.1016/j.athoracsur.2009.10.078
11. Green CP, Porter CB, Brenahan DR, Speratus JA: Development and evaluation of the Kansas City cardiomyopathy questionnaire: a new health status measure for heart failure. J Am Coll Cardiol. 2000, 35:1245-55. 10.1016/S0735-1097(00)00551-3
12. R Core Team: R: A Language and Environment for Statistical Computing . R Found Stat Comput, 2020. http://softlibre.unizar.es/manuales/aplicaciones/r/fullrefman.pdf
13. Douglas PS, Hahn RT, Pibarot P, et al.: Hemodynamic outcomes of transcatheter aortic valve replacement and medical management in severe, inoperable aortic stenosis: a longitudinal echocardiographic study of cohort B of the PARTNER trial. J Am Soc Echocardiogr. 2015, 28:210-7.e1-9. 10.1016/j.echo.2014.10.009
14. Lindman BR, Steward WJ, Pibarot P, et al.: Early regression of severe left ventricular hypertrophy after transcatheter aortic valve replacement is associated with decreased hospitalizations. JACC Cardiovasc Interv. 2014, 7:662-73. 10.1016/j.jcin.2014.02.011
15. Chau KH, Douglas PS, Pibarot P, et al.: Regression of left ventricular mass after transcatheter aortic valve replacement: the PARTNER trials and registries. J Am Coll Cardiol. 2020, 75:2446-58. 10.1016/j.jacc.2020.05.042
16. Seppelt PC, De Rosa R, Mas–Peiro S, Zeiher AM, Vasa–Nicotera M: Early hemodynamic changes after transcatheter aortic valve implantation in patients with severe aortic stenosis measured by invasive pressure volume loop analysis. Cardiovasc Interv Ther. 2020, 10.1007/s12928-020-00737-4
17. Mieghem NV, Popma J, Søndergaard L, Oh J, Chang Y, Reardon M: CRT-600.06 clinical outcomes and valve hemodynamics following transcatheter and surgical aortic valve replacement. JACC Cardiovasc Interv. 2020, 13:548. 10.1016/j.jcin.2020.01.153
18. Kodali S, Pibarot P, Douglas PS, et al.: Paravalvular regurgitation after transcatheter aortic valve replacement with the Edwards sapien valve in the PARTNER trial: characterizing patients and impact on outcomes. Eur Heart J. 2015, 56:449-56. 10.1093/eurheartj/ehu584
19. Kodali S, Thourani VH, White J, et al.: Early clinical and echocardiographic outcomes after SAPIEN 3 transcatheter aortic valve replacement in inoperable, high-risk and intermediate-risk patients with aortic stenosis. Eur Heart J. 2016, 37:2252-62. 10.1093/eurheartj/ehw112